Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

Core Viewpoint - Immunic, Inc. has appointed Jon Congleton, a biopharmaceutical executive with nearly 40 years of experience, to its Board of Directors, effective March 27, 2026, to support the company's transition into a fully integrated commercial-stage entity and advance its lead program, vidofludimus calcium, for multiple sclerosis [1][4]. Company Overview - Immunic, Inc. is a late-stage biotechnology company focused on developing novel oral therapies for neurologic diseases, with its lead program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for relapsing multiple sclerosis [4][10]. - The company aims to provide innovative solutions for patients suffering from neurologic conditions, particularly multiple sclerosis, which remains a significant challenge for patients and their families [4]. Appointment of Jon Congleton - Jon Congleton has a proven track record in building and leading biopharmaceutical organizations, having played a key role in the U.S. launch of Teva Pharmaceuticals' Copaxone®, which became the number one prescribed treatment for multiple sclerosis [2][3]. - Congleton's experience includes serving as CEO of Mineralys Therapeutics, Impel NeuroPharma, and Nivalis Therapeutics, where he guided companies from early-stage to publicly traded entities [3]. Strategic Importance - The appointment of Congleton is seen as critical for advancing Immunic's lead program, vidofludimus calcium, which is expected to offer transformative benefits for multiple sclerosis patients due to its unique combination of neuroprotective, anti-inflammatory, and anti-viral effects [4]. - The company anticipates pivotal trial readouts later in the year, which are crucial for long-term value creation and potential regulatory approval [4]. Development Pipeline - In addition to vidofludimus calcium, Immunic's development pipeline includes earlier-stage programs such as IMU-856 and IMU-381, aimed at addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases [4].